Intrathecal Triples
ApprovedSmall molecule
AmgenIntrathecal Triples is one of 119 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Approved.
4
Indications
9
Total Trials
3
Active Trials
118
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Blincyto
AmgenPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Eptanemab
UCBPhase 3
Zinecard
PfizerPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia4 trials
T-cell acute lymphoblastic leukemia2 trials
Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intrathecal Triples. EMBL-EBI & Wellcome Sanger Institute.
- [4]